ALEXANDRIA, Va., July 22, 2019 /PRNewswire/ -- Systems Planning and Analysis, Inc. (SPA) has acquired Veracity Forecasting and Analysis, Inc. (Veracity). Terms of the transaction, which closed on July 21, are not being disclosed.
Veracity provides decision support services in the government and defense sector that help large enterprises clarify complex choices. Applying operations research, data science, modeling and simulation, and predictive analytics, they develop decision support tools that improve the speed and quality of complex decision making, whether the decision involves people, places, things, or their combinations.
"With the addition of Veracity, SPA strengthens its position as a leader in operations analysis for national security and defense systems, and broadens our capabilities in the key technical areas of data science and software development," said William Vantine, CEO of SPA.
"Veracity is excited and pleased to join SPA," said Mike Macedonia, founder and CEO of Veracity. "Partnering with SPA will afford us the opportunity to offer decision support and prescriptive analytics to a broader set of government sector organizations and challenges."
Squire Patton Boggs LLP served as legal advisor to SPA. Holland and Knight LLP served as legal advisor to Veracity.
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030
The global market for Laboratory...
Reference is made to Akastor ASA's (OSE: AKAST) announcement dated 18 April 2024 on the arbitration award issued in respect of the DRU contracts. Payment of the principal sums awarded, in total USD 108 million (exclusive interest), has now been...
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...
IonQ , a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ's upcoming Annual...
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...
